Market Closed -
Euronext Paris
11:35:28 2024-06-12 am EDT
|
5-day change
|
1st Jan Change
|
0.022
EUR
|
-13.04%
|
|
-29.03%
|
-98.90%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Enterprise Value (EV)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
-
|
-
|
-
|
-
|
-
|
-
|
Reference price
2 |
400,000,000
|
525,000,000
|
283,000,000
|
165,000,000
|
9,000,000
|
1,350,000
|
Announcement Date
|
5/24/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/29/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
3.321
|
6.829
|
3.597
|
2.81
|
3.565
|
2.258
|
EBITDA
1 |
-18.07
|
-17.82
|
-19.85
|
-18.17
|
-22.2
|
-27.24
|
EBIT
1 |
-18.16
|
-17.91
|
-20.03
|
-18.91
|
-22.86
|
-27.82
|
Operating Margin
|
-546.66%
|
-262.23%
|
-556.66%
|
-672.96%
|
-641.19%
|
-1,232.02%
|
Earnings before Tax (EBT)
1 |
-20.24
|
-21.32
|
-23.31
|
-21.56
|
-30.62
|
-38.45
|
Net income
1 |
-20.24
|
-21.32
|
-23.31
|
-21.56
|
-30.62
|
-38.45
|
Net margin
|
-609.56%
|
-312.15%
|
-647.95%
|
-767.27%
|
-858.9%
|
-1,702.72%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-12.85
|
-11.28
|
-15.61
|
-10.64
|
-14.75
|
-8.646
|
FCF margin
|
-386.97%
|
-165.16%
|
-434%
|
-378.72%
|
-413.76%
|
-382.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/24/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/29/22
|
4/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
12.1
|
24.7
|
7.78
|
10.2
|
14.2
|
22.2
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.6685
x
|
-1.385
x
|
-0.3917
x
|
-0.5589
x
|
-0.6412
x
|
-0.8134
x
|
Free Cash Flow
1 |
-12.9
|
-11.3
|
-15.6
|
-10.6
|
-14.7
|
-8.65
|
ROE (net income / shareholders' equity)
|
494%
|
111%
|
139%
|
218%
|
202%
|
152%
|
ROA (Net income/ Total Assets)
|
-54%
|
-44.5%
|
-46.2%
|
-53.2%
|
-75.8%
|
-143%
|
Assets
1 |
37.5
|
47.9
|
50.44
|
40.52
|
40.41
|
26.87
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.16
|
0.39
|
0.07
|
0.02
|
0.08
|
0.04
|
Capex / Sales
|
4.83%
|
5.65%
|
2%
|
0.81%
|
2.16%
|
1.57%
|
Announcement Date
|
5/24/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/29/22
|
4/27/23
|
|
1st Jan change
|
Capi.
|
---|
| -98.90% | 4.72K | | +48.53% | 780B | | +41.73% | 627B | | +20.93% | 334B | | +8.21% | 296B | | +18.08% | 244B | | -0.90% | 217B | | +11.52% | 214B | | +4.40% | 161B | | -2.64% | 159B |
Other Pharmaceuticals
|